ライフサイエンスコーパス: tablet

1 therapy (tablets and capsules / capsules and tablets).

2 murafenib was achieved by means of a placebo tablet.

3 se for clinical efficacy of the SQ tree SLIT-tablet.

4 the efficacy and safety of the SQ tree SLIT-tablet.

5 via Bluetooth to an Android app running on a tablet.

6 me, at weekly intervals, using a loaned iPad tablet.

7 gical response in treatment with SQ HDM SLIT-tablet.

8 nths of treatment with placebo or the 300 IR tablet.

9 re within 1.3% of the overall mean of 543 mg/tablet.

10 the Gambian intervention was a micronutrient tablet.

11 hen as a single fixed-dose combination (FDC) tablet.

12 w/w during a semicontinuous manufacturing of tablets.

13 rescribed, and a 98% reduction in unconsumed tablets.

14 amian history and culture are clay cuneiform tablets.

15 n continuous manufacturing of pharmaceutical tablets.

16 ially dissolved, incongruently releasing ASD tablets.

17 e clinical development of timothy grass SLIT-tablets.

18 glass-blown cuvette cell containing five NEG tablets.

19 f reagents can be encapsulated in compressed tablets.

20 tric formulations as well as fast dissolving tablets.

21 s to accelerate drug release from 3D printed tablets.

22 o group will receive similar-looking placebo tablets.

23 n and adults treated with timothy grass SLIT-tablets.

24 of adulterated extended-release oxymorphone tablets.

25 different assay components into color-coded tablets.

26 d by the quantification of Arg in supplement tablets.

27 ecently required 25 mg and 10 mg film-coated tablets.

28 e of prasugrel either as crushed or integral tablets.

29 ascorbic acid in fruit juices and vitamin C tablets.

30 ermination in real samples of pharmaceutical tablets.

31 As such, all participants were given two tablets.

32 acebo] to 34% [SQ house dust mite sublingual tablet]).

33 thoxazole in a single fixed-dose combination tablet), 12 weeks of fluconazole, 5 days of azithromycin

34 e treatment with placebo or the SQ tree SLIT-tablet (2, 7, or 12 DU) for 24 weeks.

35 All patients were randomized 2:1 to olaparib tablets (300 mg twice daily) or single-agent chemotherap

36 s, twice daily) or vancomycin (suspension or tablets, 4 times daily).

37 herapy, 438 patients) or two matched placebo tablets (432 patients) for 12 months.

38 icipants were required to take a single oral tablet 45-60 min before physiotherapy or occupational th

39 r to remember (72.1%), required taking fewer tablets (54.0%), and to help scientific research (54.0%)

40 ding to the number of fixed-dose combination tablets [75 mg rifampicin, 50 mg isoniazid, 150 mg pyraz

41 maximum of four tablets and a minimum of one tablet a day.

42 oxycholic acid or placebo, given as two oral tablets a day at an equivalent dose of 500 mg twice a da

43 e different number of fixed dose combination tablets according to their weight-band.

44 erent number of fixed dose combination (FDC) tablets according to their weight-band.

45 hologies including thin sheets, orthorhombic tablets, acicular needles, and rosette aggregates which

46 mization to chewed (n=21) or integral (n=21) tablets administration.

47 part one of the study, and 50 mg film-coated tablets (adult dose) or 30 mg dispersible tablets in par

48 The SQ tree sublingual immunotherapy (SLIT)-tablet (ALK-Abello, Horsholm, Denmark) is developed for

49 tions for use of subcutaneous and sublingual tablet allergen immunotherapy in AR are provided.

50 The THMP included an electronic tablet and bluetooth devices to support daily text messa

51 are homes, as well as local investigation of tablet and capsule impact on medication administration e

52 All national brand name vitamins, both tablet and gel capsule formulations, and generic brands

53 l samples; this method was tested in Delmoxa tablet and human urine sample.

54 clinician's discretion, to a maximum of four tablets and a minimum of one tablet a day.

55 for another 12 weeks of continuous therapy (tablets and capsules / capsules and tablets).

56 UDCA 300 mg tablets and capsules were developed and manufactured by

57 osal delivery systems including mucoadhesive tablets and films.

58 indows, as well as between immediate release tablets and ODTs.

59 es (separated for house dust mite SCIT, SLIT tablets and SLIT drops; patient populations) including a

60 ith a different film colour), and lamivudine tablets and tenofovir disoproxil fumarate and emtricitab

61 cost interventions-low-dose oral misoprostol tablets and transcervical Foley catheterisation-are alre

62 rence between manufactured UDCA (capsule and tablet) and standard UDCA.

63 ng 20 microg of Phleum p 5 and daily placebo tablets) and 34 received matched double-placebo.

64 rint size for three digital formats (laptop, tablet, and cellphone) for 30 normally sighted and 10 lo

65 non-selenized yeast supplements in capsule, tablet, and liquid forms.

66 y of the vinegar, ascorbic acid in vitamin C tablets, and chloride in soy sauces and saline inhalatio

67 lacebo] to 5% [SQ house dust mite sublingual tablet]) and an increased probability of having a mild A

68 children given once daily 25 mg film-coated tablets (approved by the SRAs at the time of the study)

69 tion of the entire multi-particle capsule or tablet are incapable of detecting pellet-to-pellet varia

70 Both liquid extracts and tablets are approved for sublingual immunotherapy in Eur

71 Many of these tablets are damaged, leading to missing information.

72 These tablets are not readily available in low-resource settin

73 Posaconazole tablets are well tolerated and efficacious in the prophy

74 ed on video, using an in-built webcam on the tablet as well as an external camera.

75 The survey was administered by an electronic tablet-assisted face-to-face survey.

76 00 mg mirabegron (Myrbetriq extended-release tablet, Astellas Pharma) for 4 weeks in an open-label st

77 180-mg loading dose administered as crushed tablets at the time of cangrelor/placebo bolus administr

78 days were randomly assigned (1:1:1) using a tablet-based application (stratified by site) to receive

79 s recorded the residents' activities using a tablet-based application.

80 Participants were randomized to use a tablet-based decision support tool prior to 25 weeks' ge

81 Purpose To assess bone age using tablet-based US in young children living in a rural comm

82 Conclusion Bone age determined using tablet-based US was lower in children who had stunted gr

83 s and Methods From June through August 2017, tablet-based US was used to assess bone age in young chi

84 an alternating sequence on an MR-compatible tablet; before and after training, they viewed these and

85 also extended to the analysis of commercial tablets, beverage and human blood serum.Therefore, the p

86 of 2 dosages of a budesonide orodispersible tablet (BOT) vs placebo in maintaining remission of EoE.

87 tolerability of a budesonide orodispersible tablet (BOT), which allows the drug to be delivered to t

88 plus a post-sex dose); or event-driven (one tablet both before and after sex).

89 oral mifepristone 200 mg or an oral placebo tablet, both followed by a single dose of vaginal, oral,

90 0 mg/kg per day) administered as dispersible tablets, both with dose adjustment for 12 months, strati

91 we reduced the number of prescribed narcotic tablets by 96.6%.

92 mg film-coated tablets or 30 mg dispersible tablets, C(trough) was close to the adult reference (wit

93 Smartphones' and tablets' chipset/memory/operating systems differ from de

94 inated at the point of collection by a solid tablet chlorine doser (intervention group) or to be trea

95 is the key critical quality attribute for a tablet classed as an Orally Disintegrating Tablet (ODT).

96 Furthermore, the ARHMD avoided potential tablet collisions (4.8 for 3.2 seconds in Task1; 3.8 for

97 the number and duration of potential surgeon-tablet collisions avoided by the ARHMD.

98 e once a day (dolutegravir group) or a three-tablet combination of ritonavir-boosted atazanavir plus

99 The single-tablet combination treatment is intended to provide the

100 the efficacy and safety of the SQ tree SLIT-tablet compared with placebo during the BPS and TPS in a

101 ect of the SQ grass sublingual immunotherapy tablet compared with placebo on the risk of developing a

102 nically relevant effects of the SQ tree SLIT-tablet compared with placebo.

103 A tablet-compatible geosurvey and mapping system that allo

104 Raman spectroscopy of the blends just before tablet compression.

105 ask to test social reward preference using a tablet computer (iPad), where two differently coloured b

106 vascular disease risk factors by NPHWs using tablet computer-based simplified management algorithms a

107 logy Criteria for Adverse Events (CTCAE) via tablet computers at 5 successive clinic visits.

108 ommunication devices such as smartphones and tablet computers to support and improve health-related s

109 Administration of a single tablet containing 300 mg of aspirin (n = 1208) or placeb

110 The study regimen consisted of a fixed-dose tablet containing darunavir 800 mg, cobicistat 150 mg, e

111 or 311 days) or group 2 (1 identical placebo tablet containing starch with no active ingredients ever

112 d 2 years of sublingual immunotherapy (daily tablets containing 15 microg of major allergen Phleum p

113 The aim of this study with tablets containing carbamylated monomeric house dust mit

114 supplementation was 87%, assessed by monthly tablet counts.

115 econd day given 37.5 mg of prednisolone oral tablet daily (for a maximum of up to 4 days) on days whe

116 ntrol group received 37.5 mg of prednisolone tablets daily from the second day for 4 days.

117 e (200 mg) and tenofovir alafenamide (25 mg) tablets daily, with matched placebo tablets (emtricitabi

118 ) and tenofovir disoproxil fumarate (300 mg) tablets daily, with matched placebo tablets (emtricitabi

119 se of atovaquone/proguanil (250 mg/100 mg, 4 tablets/day for 3 days) provides protection against mala

120 ned education video delivered via a handheld tablet device at discharge.

121 erm uptake, compliance, and performance of a tablet device used for home monitoring of visual field (

122 ssment of the CSF that were implemented on a tablet device.

123 tableting technology, we show the ability of tableted diagnostics for screening hepatitis B-positive

124 atterns displayed on a standard LCD computer tablet, displays adaption to changes in ambient light, a

125 hospital administration of crushed prasugrel tablets does not improve TIMI 3 flow in the infarct-rela

126 High-dose deferasirox (dispersible tablet dose >30 mg/kg per day) resulted in an increased

127 per day increase in deferasirox dispersible tablet dose (equivalent to a 3.5 mg/kg per day dose of f

128 armacokinetics within-subject on film-coated tablet doses of 25 mg or 35 mg once daily, which were ap

129 at a dose of 150 mg daily) or daily placebo tablets during and after radiation therapy.

130 n reported not consuming the iron folic acid tablets during pregnancy.

131 ons for a large quantity of low-dose aspirin tablets during the 7.5-year period.

132 d combined artemether and lumefantrine (four tablets, each containing 20 mg artemether and 120 mg lum

133 (25 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir alafenamide group),

134 (300 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir disoproxil fumarate

135 n and a prescription for five 5-mg oxycodone tablets, enrolled him in the clinic's diabetes and hyper

136 The single-tablet, fixed-dose combination of elvitegravir, cobicist

137 dardised quality) house dust mite sublingual tablet for 1 year resulted in a decreased probability of

138 0 mg orally, once daily) or matching placebo tablets for 24 weeks.

139 ata in young adults, in either a once-daily (tablets; for those aged 6-17 years), twice-daily (in sus

140 Patients received 300 mg olaparib in tablet form orally twice daily for 4 weeks and thereafte

141 al brand name vitamins and generic brands in tablet form to their patients with some confidence; howe

142 capsule formulations, and generic brands in tablet form were relatively accurate in their product la

143 of a 300 index of reactivity (IR) sublingual tablet formulation of Dermatophagoides pteronyssinus:Der

144 macokinetics, and antimalarial activity of a tablet formulation of MMV390048.

145 a BRCA1 or BRCA2 (BRCA1/2) mutation using a tablet formulation of olaparib.

146 olerability of a novel orally disintegrating tablet formulation of rimegepant at 75 mg with placebo i

147 se of rimegepant in an orally disintegrating tablet formulation was more effective than placebo.

148 Both drugs were administered orally, in tablet formulation.

149 acute treatment of migraine using a standard tablet formulation.

150 Novel single tablet formulations were developed: Dactavira, composed

151 s, twice daily) or vancomycin (suspension or tablets, four times daily).

152 e learning techniques to recordings from the tablets' front-facing camera (area under the receiver op

153 Adult dolutegravir 50 mg film-coated tablets given once daily provide appropriate pharmacokin

154 rgic asthma, the cost-effectiveness of SLIT (tablets, Grazax((R)) and Oralair((R)) ) or SCIT (various

155 Asthma onset was less frequent in SLIT tablet group than in non-AIT group (odds ratio: 0.696, P

156 relative to the pretreatment period) in SLIT tablet group than in the non-AIT group (P<.001).

157 As an alternative, tablets have been used between the surgeon and the patie

158 he patient to display instructions; however, tablets impose additional obstructions of surgeon's moti

159 recent approval of a budesonide effervescent tablet in Europe; (2) biologics used for other T(H)2-med

160 f the $1638 in total payments per 30 TDF-FTC tablets in 2018, OOP payments accounted for $94 (5.7%) a

161 ake of 85% or more of the required number of tablets in 79.9% of the participants.

162 mination of Fe(3+) in spiked samples of iron tablets in different environmental water samples showed

163 ed tablets (adult dose) or 30 mg dispersible tablets in part two of the study.

164 rted to purchasing one or two 5-mg oxycodone tablets in the open-air drug market operating on the inn

165 Third-party and OOP payments per 30 TDF-FTC tablets increased annually.

166 od, the average total payment for 30 TDF-FTC tablets increased from $1350 to $1638 (5.0% compound ann

167 Here, we propose effervescent tablet-induced extraction (ETIE) as a method of transfer

168 ility of nacre can be limited by eliminating tablet interactions during crack propagations.

169 exhibit complete brittle fracture along the tablet interfaces at the proportional limit under pure s

170 The 300 IR sublingual HDM tablet is an effective, safe treatment for HDM-induced a

171 neutralization reaction, which occurs when a tablet is inserted into an aqueous sample matrix.

172 g 2000 UA/day monomeric allergoid sublingual tablets is well tolerated and reduces the CPT reaction i

173 bacterium species), or Gynophilus LP vaginal tablet (L. rhamnosus 35) for two months.

174 a newly developed orodispersible budesonide tablet licensed for the treatment of eosinophilic esopha

175 ETDRS VA or MNREAD, Ora-VCF(TM) test and Ora-tablet LL 2.0ND reading tests were able to identify sign

176 ty was 89% for both Ora-VCF(TM) test and Ora-tablet LL 2.0ND reading.

177 was 82% for Ora-VCF(TM) test and 92% for Ora-tablet LL 2.0ND reading.

178 However, the use of FDM 3D printing in tablet manufacturing requires a large portion of polymer

179 and immunological findings suggest that the tablet may be used to treat allergies to all species wit

180 in a single capsule or tablet, measurements of the dissolution of the entire mu

181 stablished the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherap

182 ved 1200 IU/d vitamin D3 (n = 77) or placebo tablets (n = 78) for 12 mo.

183 mg dispersible tablets or 50 mg film-coated tablets, none of the three reported adverse events (cryp

184 Of all the opioid tablets obtained by surgical patients, 42% to 71% went u

185 a tablet classed as an Orally Disintegrating Tablet (ODT).

186 ents aged 12-17 years received a combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir once da

187 The first received a fixed-dose combination tablet of ledipasvir-sofosbuvir (90/400 mg) once daily f

188 The tablet of multi-unit pellet system (TMUPS), using coated

189 n amount was 326 +/- 285 OME (equivalent: 65 tablets of 5 mg hydrocodone).

190 ified by site) to receive aspirin or placebo tablets of identical appearance, via a sequence generate

191 were assigned to either crushed or integral tablets of prasugrel loading dose.

192 sofosbuvir (400 mg) and velpatasvir (100 mg) tablet once daily for 12 weeks.

193 sofosbuvir (400 mg) in a single combination tablet once daily for 12 weeks.

194 s every 6 hr and fludrocortisone as a 50 mug tablet once daily).

195 ght band; then switched to 50 mg film-coated tablets once daily.

196 dihydroartemisinin-piperaquine (20 mg/160 mg tablets) once daily for 3 consecutive days every 4 weeks

197 tem, to receive oral apalutamide (four 60 mg tablets, once daily) or matching placebo.

198 ed solid, orally administered medications in tablet or capsule form at ten purposively sampled care h

199 On 50 mg film-coated tablets or 30 mg dispersible tablets, C(trough) was clos

200 p period in 47 children on 30 mg dispersible tablets or 50 mg film-coated tablets, none of the three

201 al parameters between sequence (A and B) and tablets or capsules of UDCA formulations applied in the

202 t to a 3.5 mg/kg per day dose of film-coated tablets or granules), above the typical starting dose (2

203 articipants received oral cabotegravir 30 mg tablets or matching placebo once daily during a 4 week o

204 ed (2:1) to bodyweight-adjusted rivaroxaban (tablets or suspension) in a 20-mg equivalent dose or sta

205 eive rimegepant (75 mg orally disintegrating tablet) or placebo and instructed to treat a single migr

206 two tablets per meal, 210 mg ferric iron per tablet) or usual care for 9 months or until 3 months aft

207 ere given 500 mg of levofloxacin (two 250 mg tablets), orally once daily for 12 weeks, or placebo tab

208 daily for 12 weeks, or placebo tablets (two tablets, orally once daily for 12 weeks), with dose redu

209 least two prescriptions of grass pollen SLIT tablets over at least 2 successive years were compared w

210 motherapy still had doses equivalent to five tablets per day of 5-mg hydrocodone.

211 c opioid users ( P = .05), equivalent to six tablets per day of 5-mg hydrocodone.

212 of ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet) or usua

213 (95%) of the participants took six or seven tablets per week.

214 ablished diagnosis of glaucoma were issued a tablet perimeter (Eyecatcher) and were asked to perform

215 roup) or together with a once-daily polypill tablet (polypill group).

216 uconazole and intravenous or delayed release tablet posaconazole are recommended with moderate streng

217 iation between reducing the number of opioid tablets prescribed after anterior cruciate ligament (ACL

218 a 96.6% reduction in the number of narcotic tablets prescribed, and a 98% reduction in unconsumed ta

219 nd powders within the feed frame of a rotary tablet press is used to simulate the movement of powder

220 oth optimized for use in the feed-frame of a tablet press.

221 in powder blends in the feed frame (FF) of a tablet press.

222 ecause of the much higher production rate of tableting process.

223 The use of Apps running on smartphones and tablets profoundly affects medicine.

224 In conclusion, enteric coating of V565 mini-tablets provided protection in the stomach with gradual

225 oped tests such as the Ora-VCF(TM) test, Ora-tablet reading test, color sensitivity etc.

226 his trial demonstrates that the SQ tree SLIT-tablet reduce ARC symptoms triggered by birch or oak pol

227 t with the SQ grass sublingual immunotherapy tablet reduced the risk of experiencing asthma symptoms

228 Prescription of grass pollen SLIT tablets reduced the dispensing of AR and asthma medicati

229 The single-tablet regimen consisting of bictegravir, emtricitabine,

230 t-emtricitabine-tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexpo

231 study evaluating efficacy/safety of a single-tablet regimen in a rapid initiation model of care.

232 study evaluating efficacy/safety of a single-tablet regimen in a rapid-initiation model of care.

233 ckage and subsequent treatment with a single-tablet regimen in Swiss custodial settings.

234 No once-daily single-tablet regimen is available for HIV-infected children un

235 efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine,

236 ly assigned (1:1) to receive either a single-tablet regimen of dolutegravir plus abacavir and lamivud

237 alafenamide (25 mg) or to continue a single-tablet regimen of efavirenz (600 mg), emtricitabine (200

238 randomly assigned (1:1) to receive a single-tablet regimen of either rilpivirine (25 mg), emtricitab

239 randomly assigned (1:1) to receive a single-tablet regimen of rilpivirine (25 mg), emtricitabine (20

240 alafenamide (25 mg) or to remain on a single-tablet regimen of rilpivirine (25 mg), emtricitabine (20

241 ll tolerated, and compliance with the single-tablet regimen was excellent.

242 than other integrase inhibitor-based single-tablet regimens, but long-term outcomes data are not ava

243 The locked tablets respond to strain as a continuous material, yet

244 was evaluated by comparison of the vitamin C tablet results to those obtained by iodine titration and

245 ies as well as the orodispersible budesonide tablet revealed a strong sensitization, proving a T cell

246 patients and investigate IV exposure to the tablet's inert ingredients as a possible causal mechanis

247 to tap the peak of a "sweep grating" on the tablet's touch screen.

248 P and INH in human serum, urine, saliva, and tablet samples.

249 Analysis of the formed tablets showed the drug to be evenly distributed within

250 t with the SQ grass sublingual immunotherapy tablet significantly reduced the risk of experiencing as

251 lutegravir was administered as single-entity tablets (similar to its commercial formulation, except w

252 We quantitatively separate the initial tablet sliding primarily resisted by nanoscale aragonite

253 Sublingual immunotherapy-tablet (SLIT-tablet) treatment includes the same dose re

254 samples, including cola, vinegar, an antacid tablet slurry, serum, and urine, and obtained excellent

255 with data from other phase 3 studies, single-tablet sofosbuvir-velpatasvir for 12 weeks is an efficac

256 rmulated into a fixed-dose combination (FDC) tablet (Sovodak, Rojan Pharma, Tehran, Iran).

257 We show that tableting stabilizes heat-sensitive reagents and simplif

258 anic interfaces such that adjacent inorganic tablets structurally join.

259 In the first 2 years of grass tablet sublingual immunotherapy treatment, we have previ

260 explain sustained clinical benefit of grass tablet sublingual immunotherapy.

261 to follow crystallization of indomethacin on tablet surfaces under two storage conditions: 30 degrees

262 solid-state forms and their changes on drug tablet surfaces.

263 Unlike a tablet system, the ARHMD does not require modifying natu

264 To test the clinical readiness of this tableting technology, we show the ability of tableted di

265 to less than 40 kg taking 35 mg film-coated tablets the GM C(trough) was 0.46 mg/L (63%), which was

266 the current 5FC price of US $1.30 per 500 mg tablet, the ICER of 5FC+FLU versus FLU alone was US $65

267 to less than 25 kg taking 25 mg film-coated tablets, the geometric mean (GM) C(trough) (coefficient

268 to less than 30 kg taking 25 mg film-coated tablets, the GM C(trough) was 0.39 mg/L (48%), which was

269 pepsin and amino acid hydrochloride taken as tablets three times daily for 6 weeks.

270 antibody formulated into enteric coated mini-tablets to enable release in the intestine after oral ad

271 al response of SQ house dust mite (HDM) SLIT-tablet treatment in relation to body weight in children.

272 Sublingual immunotherapy-tablet (SLIT-tablet) treatment includes the same dose regardless of t

273 drug Kolofort in monotherapy for 12 weeks, 2 tablets twice a day.

274 1,500 mg every 4 weeks with either olaparib tablets twice daily or cediranib on two schedules.

275 ive extended-pulsed fidaxomicin (200 mg oral tablets, twice daily on days 1-5, then once daily on alt

276 signed 2:1 to olaparib (300 mg in two 150 mg tablets, twice daily) or matching placebo tablets using

277 of treatment with fidaxomicin (suspension or tablets, twice daily) or vancomycin (suspension or table

278 of treatment with fidaxomicin (suspension or tablets, twice daily) or vancomycin (suspension or table

279 to receive darolutamide (600 mg [two 300-mg tablets] twice daily) or placebo while continuing androg

280 , orally once daily for 12 weeks, or placebo tablets (two tablets, orally once daily for 12 weeks), w

281 re accessible from laptops, workstations, or tablets, under Windows, macOS (and IOS), or Linux.

282 2), (b) a widely used multiple micronutrient tablet (United Nations Multiple Micronutrient Preparatio

283 mg tablets, twice daily) or matching placebo tablets using an interactive voice and web response syst

284 The 300 IR tablet was generally well tolerated.

285 h postdose, rimegepant orally disintegrating tablet was superior to placebo for freedom from pain (21

286 Median adherence to polypill tablets was 80.5% (IQR 48.5-92.2).

287 The treatment effect of timothy grass SLIT-tablets was considered similar between pediatric (n = 79

288 Fenofibrate (145 mg tablet) was self-administered daily in 10 persons with S

289 Two formulations of polypill tablet were used in this study.

290 MB-MMX and placebo tablets were administered with a 4-L polyethylene glycol

291 , AR patients treated with grass pollen SLIT tablets were compared with a control group not having re

292 Out-of-pocket payments per 30 tablets were lower among Medicaid recipients ($3) than a

293 ofovir disoproxil fumarate and emtricitabine tablets were over-encapsulated to visually match each ot

294 th active EoE, we found that budesonide oral tablets were significantly more effective than placebo i

295 es of both the drug and the polymer from ASD tablets were studied.

296 ing toothpaste, water fluoridation, fluoride tablets (which were sometimes ingested in areas with wat

297 ary reperfusion of crushed P2Y(12) inhibitor tablets, which lead to more prompt and potent platelet i

298 test for disintegration of immediate release tablets, which requires a large volume along with repeat

299 ntly worse reading performance using the Ora-tablet with LL 2.0ND (114.55 +/- 11.22 wpm in AMD; 145.1

300 The signal is captured with a smartphone or tablet working in video mode and processed by custom And